• Explore /
  • Poster
  • / Impact of acquired RAS, BRAF and PIK3CA mutation at 8 weeks on the efficacy of anti-EGFR monoclonal antibodies in metastatic colorectal cancer.

Impact of acquired RAS, BRAF and PIK3CA mutation at 8 weeks on the efficacy of anti-EGFR monoclonal antibodies in metastatic colorectal cancer.

Abstract Poster

Authors

null

Takeshi Yamada

Department of Gastrointestinal and Hepato-Billiary-Pancreatic Surgery, Nippon Medical School, Tokyo, Japan

Takeshi Yamada , Kozo Kataoka , Keita Mori , Toshihiro Kudo , Manabu Shiozawa , Naoto Takase , Kazuma Ito , Kei Kimura , Jihyung Song , Nobuhisa Matsuhashi , Toshimitsu Miyasaka , Jesse Yu Tajima , Naohito Beppu , Hirotsugu Eda , Yuka Oi , Kentaro Yamazaki , Masataka Ikeda

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Colorectal Cancer,Anal Cancer

Sub Track

Tumor Biology, Biomarkers, and Pathology

Clinical Trial Registration Number

jRCT1050210160

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr 193)

DOI

10.1200/JCO.2024.42.3_suppl.193

Abstract #

193

Poster Bd #

M1

Abstract Disclosures

Similar Posters

First Author: Gargi Dan Basu

Poster

2023 ASCO Gastrointestinal Cancers Symposium

Impact of <em>RAS </em>and<em> BRAF </em>heterogeneity on the efficacy of EGFR blockade in patients with metastatic colorectal cancer.

Impact of RAS and BRAF heterogeneity on the efficacy of EGFR blockade in patients with metastatic colorectal cancer.

First Author: Takeshi Yamada

First Author: Enrique Aranda

First Author: Dalyong Kim